Loading
A phase 2 trial of Patient-derived organoids in Non-muscle-invasive bladder cancer, run by Hospital Centre Biel/Bienne, not yet recruiting.
Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids is a phase 2 interventional study registered as NCT06227065 by Hospital Centre Biel/Bienne, with 28 participants planned, started 2026-12-01 and due to reach its primary completion in 2030-11-30. Interventions recorded: Epirubicin, Mitomycin, Gemcitabine, Docetaxel. Conditions recorded: Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low Grade.
Linked to the technology Patient-derived organoids because the registry's title names it ("patient derived organoids") and Non-muscle-invasive bladder cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Non-muscle-invasive bladder cancer, Docetaxel, Gemcitabine and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Docetaxel, Gemcitabine and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Gemcitabine and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Epirubicin, Docetaxel and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.